Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.
Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H, Fumero S, Jiménez C, Alcoceba M, Chillón MC, Sebastián E, Marín L, Montalbán MA, Mateos MV, Oriol A, Palomera L, de la Rubia J, Vidriales MB, Bladé J, Lahuerta JJ, González M, Miguel JF, García-Sanz R. Puig N, et al. Leukemia. 2014 Feb;28(2):391-7. doi: 10.1038/leu.2013.217. Epub 2013 Jul 17. Leukemia. 2014. PMID: 23860448
Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
García-Sanz R, Ocio E, Caballero A, Magalhães RJ, Alonso J, López-Anglada L, Villaescusa T, Puig N, Hernández JM, Fernández-Calvo J, Aguilar A, Martín A, López R, Paiva B, Orfao A, Vidriales B, San-Miguel JF, Del Carpio D. García-Sanz R, et al. Among authors: puig n. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):168-71. doi: 10.3816/CLML.2011.n.040. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21856552
The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution.
Puig N, Conde I, Jiménez C, Sarasquete ME, Balanzategui A, Alcoceba M, Quintero J, Chillón MC, Sebastián E, Corral R, Marín L, Gutiérrez NC, Mateos MV, González-Díaz M, San-Miguel JF, García-Sanz R. Puig N, et al. Leukemia. 2015 Jun;29(6):1435-7. doi: 10.1038/leu.2015.7. Epub 2015 Jan 8. Leukemia. 2015. PMID: 25567133 No abstract available.
Differentiation stage of myeloma plasma cells: biological and clinical significance.
Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF. Paiva B, et al. Among authors: puig n. Leukemia. 2017 Feb;31(2):382-392. doi: 10.1038/leu.2016.211. Epub 2016 Aug 1. Leukemia. 2017. PMID: 27479184 Free PMC article.
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán JJ, Vidriales MB, García-Sanz R, Jimenez C, González M, Martínez-López J, Corral-Mateos A, Grigore GE, Fluxá R, Pontes R, Caetano J, Sedek L, Del Cañizo MC, Bladé J, Lahuerta JJ, Aguilar C, Bárez A, García-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, van Dongen JJM, Orfao A. Flores-Montero J, et al. Among authors: puig n. Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20. Leukemia. 2017. PMID: 28104919 Free PMC article.
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jimenez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martin-Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, Lahuerta JJ. Martinez-Lopez J, et al. Among authors: puig n. Leukemia. 2017 Jun;31(6):1446-1449. doi: 10.1038/leu.2017.58. Epub 2017 Feb 17. Leukemia. 2017. PMID: 28210002 Free PMC article. Clinical Trial. No abstract available.
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.
Arana P, Paiva B, Cedena MT, Puig N, Cordon L, Vidriales MB, Gutierrez NC, Chiodi F, Burgos L, Anglada LL, Martinez-Lopez J, Hernandez MT, Teruel AI, Gironella M, Echeveste MA, Rosiñol L, Martinez R, Oriol A, De la Rubia J, Orfao A, Blade J, Lahuerta JJ, Mateos MV, San Miguel JF. Arana P, et al. Among authors: puig n. Leukemia. 2018 Apr;32(4):971-978. doi: 10.1038/leu.2017.320. Epub 2017 Nov 3. Leukemia. 2018. PMID: 29099494 Free article. Clinical Trial.
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.
González-Calle V, Dávila J, Escalante F, de Coca AG, Aguilera C, López R, Bárez A, Alonso JM, Hernández R, Hernández JM, de la Fuente P, Puig N, Ocio EM, Gutiérrez NC, García-Sanz R, Mateos MV. González-Calle V, et al. Among authors: puig n. Leukemia. 2016 Oct;30(10):2026-2031. doi: 10.1038/leu.2016.123. Epub 2016 May 2. Leukemia. 2016. PMID: 27133826
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).
Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Puig N, García-Mateo A, García-Sánchez O, Corral-Mateos A, Burgos L, Blanco E, Hernández-Martín J, Pontes R, Díez-Campelo M, Millacoy P, Rodríguez-Otero P, Prosper F, Merino J, Vidriales MB, García-Sanz R, Romero A, Palomera L, Ríos-Tamayo R, Pérez-Andrés M, Blanco JF, González M, van Dongen JJM, Durie B, Mateos MV, San-Miguel J, Orfao A; EuroFlow consortium. Sanoja-Flores L, et al. Among authors: puig n. Blood Cancer J. 2018 Nov 19;8(12):117. doi: 10.1038/s41408-018-0153-9. Blood Cancer J. 2018. PMID: 30455467 Free PMC article.
Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain).
Alcoceba M, Marín L, Balanzategui A, Sarasquete ME, Chillón MC, Martín-Jiménez P, Puig N, Santamaría C, Corral R, García-Sanz R, San Miguel JF, González M. Alcoceba M, et al. Among authors: puig n. Tissue Antigens. 2011 Oct;78(4):249-55. doi: 10.1111/j.1399-0039.2011.01766.x. Tissue Antigens. 2011. PMID: 21929573
218 results